MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf‑related protein 3

Zhang,Xiao‑Long; Xu,Gang; Zhou,Yi; Yan,Jia‑Jun

doi:10.3892/ol.2018.7998

MicroRNA-183 promotes the proliferation and metastasis of renal cell carcinoma through targeting Dickkopf‑related protein 3

Authors:
- Xiao‑Long Zhang
- Gang Xu
- Yi Zhou
- Jia‑Jun Yan
View Affiliations

Affiliations: Department of Urology, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, P.R. China
Published online on: February 8, 2018 https://doi.org/10.3892/ol.2018.7998
Pages: 6003-6008

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is insensitive to conventional chemotherapy and radiotherapy, and its prognosis remains poor. Targeted therapy is a novel technique for the treatment of RCC. The present study aimed to determine the precise effects of microRNA-183 (miR‑183) on RCC. Reverse transcription‑quantitative polymerase chain reaction analysis was conducted in order to analyze the expression level of miR‑183 in RCC cell lines. Cell transfection, viability assays and invasion assays were also performed, followed by western blot analysis and a luciferase reporter assay, in order to examine the effects of miR‑183. The expression of miR‑183 was upregulated in all four RCC cell lines compared with the immortalized normal proximal tubule epithelial HK‑2 cell line. The cell viability and invasion assays demonstrated that decreased expression of miR‑183 suppressed RCC cell proliferation and invasion in vitro. Furthermore, the present study identified that Dickkopf‑related protein-3 (DKK‑3) was a direct target of miR‑183 in RCC. The results demonstrated that miR‑183 functioned as an oncogene by downregulating DKK‑3 expression and that it provided a potential diagnostic, prognostic and therapeutic target for RCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A and Bray F: International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015. View Article : Google Scholar : PubMed/NCBI
3	Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, et al: Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. J Clin Oncol. 23:2763–2771. 2005. View Article : Google Scholar : PubMed/NCBI
4	Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A, Canfield SE, Staehler M, et al: Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus. Eur Urol. 70:265–280. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
6	Moch H, Cubilla AL, Humphrey PA, Reuter VE and Ulbright TM: The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: Renal, penile, and testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
7	Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, et al: Efficacy of second-line targeted therapy for renal cell carcinoma according to change from baseline in international metastatic renal cell carcinoma database consortium prognostic category. Eur Urol. 71:970–978. 2017. View Article : Google Scholar : PubMed/NCBI
8	Cloney R: Non-coding RNA: Deciphering the rules of microRNA targeting. Nat Rev Genet. 17:7182016. View Article : Google Scholar : PubMed/NCBI
9	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
10	He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
11	Matsui M and Corey DR: Non-coding RNAs as drug targets. Nat Rev Drug Discov. 16:167–179. 2017. View Article : Google Scholar : PubMed/NCBI
12	Lumayag S, Haldin CE, Corbett NJ, Wahlin KJ, Cowan C, Turturro S, Larsen PE, Kovacs B, Witmer PD, Valle D, et al: Inactivation of the microRNA-183/96/182 cluster results in syndromic retinal degeneration. Proc Natl Acad Sci USA. 110:pp. E507–E516. 2013; View Article : Google Scholar : PubMed/NCBI
13	Huangfu L, Liang H, Wang G, Su X, Li L, Du Z, Hu M, Dong Y, Bai X, Liu T, et al: miR-183 regulates autophagy and apoptosis in colorectal cancer through targeting of UVRAG. Oncotarget. 7:4735–4745. 2016. View Article : Google Scholar : PubMed/NCBI
14	Miao F, Zhu J, Chen Y, Tang N, Wang X and Li X: MicroRNA-183-5p promotes the proliferation, invasion and metastasis of human pancreatic adenocarcinoma cells. Oncol Lett. 11:134–140. 2016. View Article : Google Scholar : PubMed/NCBI
15	Zhu C, Deng X, Wu J, Zhang J, Yang H, Fu S, Zhang Y, Han Y, Zou Y, Chen Z and Lin S: MicroRNA-183 promotes migration and invasion of CD133(+)/CD326(+) lung adenocarcinoma initiating cells via PTPN4 inhibition. Tumour Biol. 37:11289–11297. 2016. View Article : Google Scholar : PubMed/NCBI
16	Li C, Deng L, Zhi Q, Meng Q, Qian A, Sang H, Li X and Xia J: MicroRNA-183 functions as an oncogene by regulating PDCD4 in gastric cancer. Anticancer Agents Med Chem. 16:447–455. 2016. View Article : Google Scholar : PubMed/NCBI
17	Cheng Y, Xiang G, Meng Y and Dong R: MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4. Reprod Biol. 16:225–233. 2016. View Article : Google Scholar : PubMed/NCBI
18	Fan D, Wang Y, Qi P, Chen Y, Xu P, Yang X, Jin X and Tian X: MicroRNA-183 functions as the tumor suppressor via inhibiting cellular invasion and metastasis by targeting MMP-9 in cervical cancer. Gynecol Oncol. 141:166–174. 2016. View Article : Google Scholar : PubMed/NCBI
19	Zhang Q, Di W, Dong Y, Lu G, Yu J, Li J and Li P: High serum miR-183 level is associated with poor responsiveness of renal cancer to natural killer cells. Tumour Biol. 36:9245–9249. 2015. View Article : Google Scholar : PubMed/NCBI
20	Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 108:1659–1667. 2013. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Bi DP, Yin CH, Zhang XY, Yang NN and Xu JY: MiR-183 functions as an oncogene by targeting ABCA1 in colon cancer. Oncol Rep. 35:2873–2879. 2016. View Article : Google Scholar : PubMed/NCBI
23	Klaus A and Birchmeier W: Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 8:387–398. 2008. View Article : Google Scholar : PubMed/NCBI
24	Veeck J and Dahl E: Targeting the Wnt pathway in cancer: The emerging role of Dickkopf-3. Biochim Biophys Acta. 1825:18–28. 2012.PubMed/NCBI
25	Ueno K, Hirata H, Majid S, Chen Y, Zaman MS, Tabatabai ZL, Hinoda Y and Dahiya R: Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma. Mol Carcinog. 50:449–457. 2011. View Article : Google Scholar : PubMed/NCBI
26	Guo CC, Zhang XL, Yang B, Geng J, Peng B and Zheng JH: Decreased expression of Dkk1 and Dkk3 in human clear cell renal cell carcinoma. Mol Med Rep. 9:2367–2373. 2014. View Article : Google Scholar : PubMed/NCBI